Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2013-11, Vol.15 (11), p.1040-1048
• Main Authors: Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., Flint, A.
• Format: Article
• Language: English
• Subjects: Aged; antidiabetic drug; Antidiabetics; Apolipoproteins; Body Mass Index; Cardiovascular diseases; Cardiovascular Diseases - complications; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cholesterol; Cross-Over Studies; Denmark - epidemiology; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diet; Diet, High-Fat - adverse effects; Double-Blind Method; Fatty acids; Female; Gastric emptying; Gastric Emptying - drug effects; Germany - epidemiology; GLP-1 analogue; Glucagon; Glucagon-Like Peptide 1 - adverse effects; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - blood; Glucagon-Like Peptide 1 - pharmacokinetics; Glucagon-Like Peptide 1 - therapeutic use; Half-Life; Humans; Hyperlipidemias - complications; Hyperlipidemias - etiology; Hyperlipidemias - prevention & control; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - adverse effects; Hypolipidemic Agents - blood; Hypolipidemic Agents - pharmacokinetics; Hypolipidemic Agents - therapeutic use; lipid-lowering therapy; Lipids; Lipids - blood; Liraglutide; Male; Middle Aged; Obesity - complications; Paracetamol; phase I-II study; Placebos; Postprandial Period; randomized trial; Risk Factors; type II diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.12133

Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady‐state liraglutide 1.8 mg versus placebo on postprandial plasma lipid concentrations after 3 weeks of treatment in patients with type 2 diabetes mellitus (T2DM). Methods In a cross‐over trial, patients with T2DM (n = 20, 18–75 years, BMI 18.5–40 kg/m2) were randomized to once‐daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo. After each 3‐week period, a standardized fat‐rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC0–8h), apolipoprotein B48, non‐esterified fatty acids, glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: NCT00993304. Funding: Novo Nordisk A/S. Results After 3 weeks, mean postprandial triglyceride (AUC0–8h liraglutide/placebo treatment‐ratio 0.72, 95% CI [0.62–0.83], p = 0.0004) and apolipoprotein B48 (AUC0–8h ratio 0.65 [0.58–0.73], p